FDA (Food and Drug Administration). 2001. Vaccine Adverse Event Reporting System (VAERS) Frequently Asked Questions. [Online]. Available: http://www.fda.gov/cber/vaers/faq.htm [accessed May 24, 2001].


GAO (General Accounting Office). 2000. Anthrax Vaccine: Preliminary Results of GAO’s Survey of Guard/Reserve Pilots and Aircrew Members. GAO-01-92T. Washington, D.C.: GAO.

Grabenstein JD. 2001a. Technical review comments. Excerpted draft sections for DoD/AVIP technical review. Anthrax Vaccine Immunization Program Agency, Falls Church, Va., December 7 .

Grabenstein JD. 2001b. Vaccine Adverse Events Reporting System. E-mail to Joellenbeck L, Institute of Medicine, Washington, D.C., August 3.

Grabenstein JD. 2001c. Acute allergic reactions after anthrax vaccination. Information paper. Anthrax Vaccine Immunization Program Agency, Falls Church, Va.


IOM (Institute of Medicine). 1994a. Stratton KR, Howe CJ, Johnston RB Jr, eds. Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality. Washington, D.C.: National Academy Press.

IOM. 1994b. Stratton KR, Howe CJ, Johnston RB Jr, eds. Research Strategies for Assessing Adverse Events Associated with Vaccines: A Workshop Summary. Washington, D.C.: National Academy Press.

Irelan, J. 2000. Anthrax Vaccine Immunization Progam—What Have We Learned? Statement at the October 3, 2000, hearing of the Committee on Government Reform, U.S. House of Representatives, Washington, D.C.

Iskander J. 2001a. Detection of duplicate VAERS reports. E-mail to Joellenbeck L, Institute of Medicine, Washington, D.C., August 3.

Iskander J. 2001b. Technical review. E-mail to Joellenbeck L, Institute of Medicine, Washington, D.C., June 1.

Iskander J. 2002. Number of VAERS reports filed for all vaccines. E-mail to Joellenbeck L, Institute of Medicine, Washington, D.C., February 8.


Kerrison JB, Lounsbury D, Thirkill CE, Lane RG, Schatz MP, Engler RM. 2002. Optic neuritis after anthrax vaccination. Ophthalmology 109(1):99–104.


Mootrey G. 2000. The Vaccine Adverse Event Reporting System (VAERS) and anthrax vaccine. Presentation to the Institute of Medicine Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Meeting I, Washington, D.C.


Nietupski J. 2001. Statement and documents submitted for the Joint Meeting of the Institute of Medicine Committee to Assess the Safety and Efficacy of the Anthrax Vaccine and the Institute of Medicine Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program, Meeting III, Washington, D.C.


Peake JB. 2000. Reactions to Vaccines. Memorandum to Commanders of the North Atlantic, Southeast, Great Plains, Western, European, and Pacific Regional Medical Commands. Department of the Army, Washington, D.C.


Rosenthal S, Chen R. 1995. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. American Journal of Public Health 85(12):1706–1709.


Sever JL, Brenner AI, Gale AD, Lyle JM, Moulton LH, West DJ. In press. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiology and Drug Safety.

Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT. 1999. An overview of the Vaccine Adverse Event Reporting System (VAERS) as a surveillance system. VAERS Working Group. Vaccine 17(22):2908–2917.

Surgeon General of the Navy. 2000. Handling persons with reactions to anthrax vaccine. Memorandum. Department of the Navy, Washington, D.C.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement